Use of Fresh Platelet Rich Plasma With Concentrated Leukocytes or Fresh Platelet Rich Plasma With… (NCT04187183) | Clinical Trial Compass
CompletedNot Applicable
Use of Fresh Platelet Rich Plasma With Concentrated Leukocytes or Fresh Platelet Rich Plasma Without Concentrated Leukocytes in the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial
Italy132 participantsStarted 2020-06-23
Plain-language summary
The aim of the study is to compare the triple infiltration of Fresh Platelet Rich Plasma with concentrated Leukocytes against triple infiltration of Fresh Platelet Rich Plasma Without Concentrated Leukocytes in the treatment of Knee Cartilage Degeneration in a Double Blind Randomized Controlled Trial
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between 18 and 75 years;
✓. Unilateral involvement;
✓. Signs and symptoms of degenerative pathology of the cartilage of the knee;
✓. Radiographic or MRI signs of degenerative pathology of the cartilage of the knee (Kellgren-Lawrence 1-4 degrees);
✓. Hemoglobin\> 11 g / dl; Platelet count\> 150,000 plt / mm3 (recently performed blood count);
✓. No clinically significant electrocardiographic alteration (recently performed ECG).
✓. Patients' ability and consent to actively participate in clinical follow-up;
✓. Signature of informed consent.
Exclusion criteria
✕. Patients undergone to intra-articular infiltration of another substance in the previous 6 months;
✕. Patients undergone knee surgery in the previous 12 months;
✕. Patients with malignant neoplasms;
✕. Patients suffering from rheumatic diseases;
✕. Patients suffering from diabetes;
✕. Patients with hematologic diseases (coagulopathies);
What they're measuring
1
IKDC-subjective score (International Knee Documentation Committee)